Form 4: IN8BIO Chief Medical Officer Receives Stock Option Award
SEC Form 4 Filing
Trishna Goswami, Chief Medical Officer of IN8BIO, Inc., was granted a stock option to purchase 250,000 shares of common stock as a retention award.
Summary
- Trishna Goswami, the Chief Medical Officer of IN8BIO, Inc., received a stock option on September 4, 2024.
- The option allows her to purchase 250,000 shares of IN8BIO's common stock at an exercise price of $0.47 per share.
- This option serves as a retention award, incentivizing her continued service with the company.
- The options vest in installments: 25% on March 4, 2025, 25% on September 4, 2025, and the remaining 50% on March 4, 2026, contingent upon her continued employment.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. It's a positive sign for retention.
Positives
- The stock option award aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
- The vesting schedule encourages continued service and commitment from a key member of the management team.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies like IN8BIO.
- Comparable companies such as Celldex Therapeutics or Ziopharm Oncology also utilize stock options as part of their executive compensation strategy.
- The vesting schedule and exercise price are typical for retention awards in the industry.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company performance.
- Employees may see this as a sign of investment in key personnel.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of the stock option grant. |
| 03/04/2025 | First vesting date (25% of shares). |
| 09/04/2025 | Second vesting date (25% of shares). |
| 03/04/2026 | Final vesting date (50% of shares). |
| 09/04/2034 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.